Electronic Journal of IFCC (eJIFCC) is officially indexed by MEDLINE/PUBMED. All issues from 1999 onward are available online and are indexed, searchable, downloadable, and citable from PubMed.
To receive the eJIFCC:
Please Click here and select "Subscribe" among the options, thank you
eJIFCC Volume 32 no 1 - 2021
|In this issue: Measurably better healthcare|
|Click here to download a PDF of the full issue.|
|1||Foreword: Measurably better health care – signs of a (r)evolution in progress towards a new academic science?|
Guest editors: Tim J. James, Ellie Dow
|2||Laboratory medicine and healthcare excellence – till death do us part|
Colleen Strain, Tricia H. Ravalico
|3||Procalcitonin (PCT) level in the emergency department identifies a high-risk cohort for all patients treated for possible sepsis|
Georgia Lucas, Angela Bartolf, Nicholas Kroll, Agampodi-Umanda De Thabrew, Zoya Murtaza, Siddarth Kumar, Abrar Gani, Andrea Annoni, Marie Parsons, Helen Pardoe
|4||Reducing patient risk and enhancing care through the development and implementation of a new chest pain pathway, expedited by and for the COVID-19 era|
Martin P. Than, John W. Pickering, Philip Adamson, Thomas Clendon, Christopher M. Florkowski, John Lainchbury, Jacques Loubser, Alison Nankivel, Sally J. Aldous
|5||Avoiding insufficient therapies and overdosing with co-reporting eGFRs (estimated glomerular filtration rate) for personalized drug therapy and improved outcomes – a simulation of the financial benefits|
Adrian Hoenle, Karin Johanna Haase, Sebastian Maus, Manfred Hofmann, Matthias Orth
|6||The use of faecal haemoglobin in deciding which patients presenting to primary care require further investigation (and how quickly) – the FIT approach|
Judith A. Strachan, Craig Mowat
|7||The Kidney Check program – championing patient-centered, culturally safe, preventive kidney care in Canada’s rural and remote Indigenous communities|
Sarah Curtis, David Collister, Heather Martin, Abdul Razaq Sokoro, Lorraine McLeod, Caroline Chartrand, Barry Lavallee, Cathy Woods, Adeera Levin, Paul Komenda
|8||Is COVID-19 impacting prostate cancer screening? A survey of prostate-specific antigen test requests during a local outbreak|
Anna Ferrari, Fabian Sanchis-Gomar, Camilla Mattiuzzi, Brandon M. Henry, Giuseppe Lippi
|9||Monitoring of diabetic patients with poor glycemic control. Are international recommendations met?|
José Antonio Delgado, Josep Miquel Bauça
|10||Multicenter survey of physicians’ perception of interpretative commenting and reflective testing in Nigeria|
Lucius Chidiebere Imoh, Chinelo Pamela Onyenekwu, Kenneth Ogar Inaku, Alexander Oghielu Abu, Chibuzo David Tagbo, Idris Yahaya Mohammed, Modupe Akinrele Kuti
|11||E-gene RT-PCR crossing point value and other biochemical parameters as useful markers of death risk in COVID-19 patients|
Alba Bellés-Bellés, María Bernal, Javier Gómez-Arbonés, Albert Bernet, Silvia Picó, Jessica Bueno, Carlos Chávez, Mercè García-González, Mercè Ibarz
|12||Diabetic euglycemic ketoacidosis induced by oral antidiabetics type SGLT2i|
Guillermo Velasco de Cos, María Isabel Sánchez-Molina Acosta, María Matilde Toval Fernández
Faculty of Medicine
University of Debrecen
|Harjit Pal Bhattoa|
Department of Laboratory Medicine University of Debrecen
Khosrow Adeli, The Hospital for Sick Children, University of Toronto, Canada
Edgard Delvin, CHU Sainte-Justine Research Center, Montréal, Québec, Canada
Nilda E. Fink, Universidad Nacional de La Plata, Argentina
Ronda Greaves, Biochemical Genetics, Victorian Clinical Genetics Services, Victoria, Australia
Mike Hallworth, Shrewsbury, United Kingdom
Andrea R. Horvath, Prince of Wales Hospital and School of Medical Sciences, University of New South Wales, Sydney, Australia
Ellis Jacobs, EJ Clinical Consulting, LLC, USA
Allan S. Jaffe, Mayo Clinic, Rochester, USA
Bruce Jordan, Roche Diagnostics, Rotkreuz, Switzerland
Evelyn Koay, National University, Singapore
Tamas Kőszegi, University of Pécs, Pécs, Hungary
Gábor L. Kovács, University of Pécs, Pécs, Hungary
Gabriel Lima-Oliveira, University of Verona, Italy
Janja Marc, University of Ljubljana, Ljubljana, Slovenia
Gary L. Myers, Joint Committee for Traceability in Laboratory Medicine, USA
Tomris Ozben, Akdeniz University, Antalya, Turkey
Maria D. Pasic, Laboratory Medicine and Pathobiology, University of Toronto, Canada
Maria del C. Pasquel Carrera, College of Chemists, Biochemists and Pharmacists, Pichincha, Ecuador
Oliver Racz, University of Kosice, Slovakia
Rosa Sierra Amor, Laboratorio Laquims, Veracruz, Mexico
Sanja Stankovic, Institute of Medical Biochemistry, Clinical Center of Serbia, Belgrade, Serbia
Danyal Syed, Ryancenter, New York, USA
Grazyna Sypniewska, Collegium Medicum, NC University, Bydgoszcz, Poland
Peter Vervaart, LabMed Consulting, Australia
Stacy E. Walz, Arkansas State University, USA
IFCC Communications and Publications Division (IFCC-CPD)
Copyright © 2000-2021 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved.
This is a Platinum Open Access Journal distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The electronic Journal of the IFCC (eJIFCC) is a platinum open-access journal, i.e. there is no charge to read, or to submit to this journal. Our numerous high-quality articles, debates, reviews, case studies and editorials are addressed to clinical laboratorians. The journal also publishes general news articles, IFCC publicity/news, educational materials and has a letters section. Besides offering original scientific thought in our featured columns, we provide pointers to quality resources on the world wide web. We aim to assist the development of the field of clinical chemistry and laboratory medicine worldwide.
Manuscripts are fully peer reviewed and immediately free to access and download from www.ifcc.org.
The eJIFCC is a member of the Committee on Publications Ethics (COPE).
eJIFCC is archived by PubMedCentral (http://www.ncbi.nlm.nih.gov).
eJIFCC is included in Scopus.
Manuscript preparation: Microsoft Word is preferred, with the use of 12-point font, 2cm margins and double spacing. The title page should list title, authors (first name, last name and initials), each author's affiliation during the study, including e-mail adresses, corresponding author's contact information, key words. All manuscript should be provided with structured Abstracts not longer than 250 words. This information should proceed the text of each submission. Tables should be created in a common word-processing or spreadsheet format and included within the text of the manuscript, close to the first location where they are referenced. The figures must be submitted as independent images or files, with high enough resolution for publishing and printing. All tables and figures must include a short title, with any further explanatory text to be included at the bottom of either. The maximum number of references for a review article is 75, and 40 for original papers. In-text reference numbers should be included paranthetically before punctuation. The actual references shall be presented and punctuated consistently and are to be listed sequentially following the main text, with their numbers unlinked. Manuscripts should provide any required Author's Disclosures. All studies involving human subjects must indicate that they are in compliance with the ethical principles for medical research involving human subjects, in accordance with the Declaration of Helsinki.
The eJIFCC welcomes case reports that illustrate new approaches to established clinical - diagnostic problems or describing a new clinically associated diagnostic problem. To be of value appropriate for publication, a case report must provide a significant learning point for other laboratory physicians and clinical chemists. Case reports should be provided with a summary not longer than 150 words, followed by a structured main text (INTRODUCTION, CLINICAL-DIAGNOSTIC CASE, DISCUSSION, TAKE HOME MESSAGES/LEARNING POINTS) not exeeding 1500 words. Case reports will also allow 2 tables and 2 figures, the maximum number of references is 15, 3-5 keywords are mandatory. Please provide disclosures & contribution of authors at the end of manuscript text.
Submission of manuscripts: Manuscripts should be submitted to the editor-in-chief, via e-mail to: email@example.com.